Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

NCT04888481 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT04888481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04888481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Lead sponsor
University of Alberta
Phase
Phase 2
Overall status
Recruiting
Start date
February 15, 2022
Completion date
August 31, 2028
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors